Eli Lilly disclosed preliminary findings from several obesity studies ahead of ObesityWeek 2026. In the Phase II EloraTZP trial, combining eloralintide with tirzepatide produced mean weight loss of up to 23.3% at 48 weeks in adults with overweight or obesity and type 2 diabetes, alongside mean glycated hemoglobin (HbA1c) reductions of up to 2.9 percentage points. In the Phase III SURMOUNT-ADOLESCENTS program, Zepbound (tirzepatide) produced an average 21.4% body mass index (BMI) reduction at 72 weeks in adolescents aged 12–18 with obesity. Complete results, including the detailed safety and comparator analyses, were not yet available in the Reuters report.
Reuters
Why it matters strategically
The results create two distinct development opportunities: combining metabolic mechanisms to improve adult treatment outcomes and expanding an established obesity medicine into adolescent care.
For developers, the important question is whether additional weight loss produces sufficient incremental clinical value to justify added treatment complexity, development costs, and potentially higher reimbursement demands.